icon
icon

About Us

Success Stories

Careers

Quick Links

Contact

Media

Find A Doctor

Dr. Karan Kumar

Associate Professor

Book an Appointmentarrow
chairperson

Dr. Karan Kumar is an Associate Professor of Hepatology and Liver Transplantation at Mahatma Gandhi Medical College & Hospital, Jaipur. He completed his MD in Internal Medicine from B. J. Medical College, Ahmedabad, followed by a Doctorate in Medicine (DM) in Hepatology from the Institute of Liver and Biliary Sciences (ILBS), New Delhi. He subsequently worked as a Consultant at BGS Gleneagles Global Hospital, Bengaluru, gaining further experience in advanced hepatology and liver transplantation.

Dr. Kumar has extensive experience in the management of complex liver diseases, with special interests in acute liver failure, acute-on-chronic liver failure, refractory ascites and portal hypertension, alcohol-associated liver disease, and hepatocellular carcinoma. He is actively involved in liver transplantation, including pre-transplant evaluation and optimization, peri-transplant management, management of post-transplant complications, and long-term care of transplant recipients. He has also been closely involved in the development and growth of the liver transplant program at Mahatma Gandhi Hospital, Jaipur, contributing to the establishment of advanced and complex liver transplantation services in Rajasthan.

Dr. Kumar has a strong academic and research profile, with more than 50 publications in national and international peer-reviewed journals and contributions to five book chapters in hepatology and liver transplantation. He serves as a Science Editor for the Indian Journal of Gastroenterology and is a peer reviewer for several national and international medical journals.

He has contributed to important national and international academic initiatives in hepatology, including the INASL Puri Consensus Guidelines on Hepatocellular Carcinoma, and is a member of the APASL Kyoto Consensus Group, contributing to collaborative efforts toward evidence-based recommendations in liver disease.

He is a member of the Young Hepatology Forum of the Indian National Association for Study of the Liver (INASL) and a life member of INASL, the Liver Transplant Society of India (LTSI), and the Indian Society of Gastroenterology (ISG).

His professional interests encompass advanced clinical hepatology, liver transplantation, clinical research, scientific publishing, and medical education, with a focus on improving evidence-based care for patients with complex and advanced liver diseases.

  • Awarded Poster of Distinction at “The Liver Meeting” By American Association of Study of Liver Disease (AASLD) at San Francisco 2018
  • Best Oral Paper Presentation at “The International Liver congress” by European association of Study of Liver (EASL) at Vienna Austria-2019
  • Awarded Associate Fellow by National Academy of Medical Sciences-2022
  • Best oral paper presentation at APASL 2025, Beijing,China
  • INASL
  • Liver Transplant Society of India
  • The Indian Society of Gastroenterology.
  • Life Member of Indian Society of Organ Transplant (ISOT).
Sr. No Cite (Vancouver)
1 Kumar K, Kulkarni AV, Sarin SK, Choudhury A, Shashthry SM, Anand L. Role of microRNA in acute cellular rejection. Hepatology. 2017 Apr;65(4):1423-4.
2 Kumar K, Mishra M. Prevention of paracentesis-induced circulatory dysfunction-a systematic review and network meta-analysis. GastroHep. 2020 May;2(3):138-.
3 Kumar K, Perricone G, Mancuso A, Belli LS. Acute-on-Chronic Liver Failure. New England Journal of Medicine. 2020 Aug 27;383(9):893.
4 Kumar K, Mishra M. moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Alimentary Pharmacology & Therapeutics. 2020 Aug 1;52(3).
5 Kumar K, Kulkarni A. Elevated Liver Chemistries in COVID-19—Is It Not a Concern?. Official journal of the American College of Gastroenterology| ACG. 2021 Feb 1;116(2):424.
6 Kumar K, Dixit I. TIPSS and reversal of sarcopenia. Alimentary Pharmacology & Therapeutics. 2021 Jan 1;53(1).
7 Kumar K, Varghese J, Malleeswaran S, Patcha RV, Appusamy E, Karnan P, Kapoor D, Venugopal K, Kedarisetty CK, Singh B, Rao PS, Yalakanti RB. A multicentric experience on living donor liver transplantation in coronavirus disease 2019 hotspots in India. Liver Transplantation. 2021 Sep;27(9):1334-8.
8 Kumar K, Kulkarni A. Sodium-Glucose Cotransporter-2 Inhibitors Are Not the Magic Pills for Control of Ascites in Cirrhosis and Diabetes. Hepatology. 2021 Feb 1;73(2):865.
9 Kumar K, Dixit I. Retreatment Decision for Hepatitis B Flare in HBeAg-Negative Chronic Hepatitis B. Hepatology. 2021 May 1;73(5):2081-2.
10 Kumar K, Kulkarni AV, Candia R, Arab JP, Tevethia HV, Premkumar M, Sharma M, Menon B, Rao GV, Reddy ND, Rao NP. Prophylactic perioperative terlipressin therapy for preventing acute kidney injury in living donor liver transplant recipients: a systematic review and meta-analysis. Journal of Clinical and Experimental Hepatology. 2022 Mar 1;12(2):417-27.
11 Kumar K, Kulkarni AV, Tevethia HV, Premkumar M, Arab JP, Candia R, Kumar P, Sharma M, Rao PN, Reddy DN. Impact of COVID-19 on liver transplant recipients–A systematic review and meta-analysis. EClinicalMedicine. 2021 Aug 1;38.
12 Kumar K, Kulkarni A, Jagdish RK. Saroglitazar for Treatment of NAFLD and NASH. Hepatology. 2021 Dec 1;74(6):3559-60.
13 Kumar K, Kulkarni AV, Tirumalle S, Premkumar M, Fatima S, Rapole B, Simhadri V, Gora BA, Sasikala M, Gujjarlapudi D, Yelamanchili S. Primary norfloxacin prophylaxis for APASL-defined acute-on-chronic liver failure: a placebo-controlled double-blind randomized trial. Official journal of the American College of Gastroenterology| ACG. 2022 Apr 1;117(4):607-16.
14 Kumar K, Saraswat VA. Untangling the web of malnutrition, sarcopenia, and frailty in chronic liver disease. Journal of Clinical and Experimental Hepatology. 2022 Mar 17;12(2):268.
15 Kumar K, Kulkarni AV, Ravikumar ST, Tevethia H, Premkumar M, Sharma M, Gupta R, Rao PN, Reddy DN. Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study. Scientific Reports. 2022 Apr 1;12(1):5503.
16 Kumar K, Kulkarni AV, Premkumar M, Rao PN, Reddy DN. Response to Mir et al. Official journal of the American College of Gastroenterology| ACG. 2022 May 1;117(5):816.
17 Kumar K, Kulkarni A, Mahala VK, Saraswat VA. Early prediction of decompensation in cirrhosis—Is it possible without aetiology and portal hypertension?. Liver International. 2022 May 1;42(5).
18 Kumar K, Kulkarni AV, Premkumar M, Arab JP, Sharma M, Reddy ND, Padaki NR, Reddy RK. Early diagnosis and prevention of infections in cirrhosis. InSeminars in Liver Disease 2022 Aug (Vol. 42, No. 03, pp. 293-312). Thieme Medical Publishers, Inc..
19 Kumar K, Kulkarni AV, Hanchanale P, Prakash V, Kalal C, Sharma M, Bishnu S, Kulkarni AV, Anand L, Patwa AK, Kumbar S. Tinospora cordifolia (Giloy)–Induced liver injury during the COVID-19 pandemic—multicenter nationwide study from India. Hepatology Communications. 2022 Jun 1;6(6):1289-300.
20 Kumar K, Kulkarni AV, Premkumar M, Khan JA, Gora BA, Tirumalle S, Shaik S, Sharma M, Gupta R, Reddy ND, Rao PN. Nonselective beta-blockers reduce mortality in patients with acute-on-chronic liver failure. Potal Hypertension & Cirrhosis. 2022 Jun 30;1(01):15-22.
21 Kumar K, Islam M, Sevak JK, Jindal A, Vyas AK, Ramakrishna G, Kottilil S, Sharma MK, Sarin SK, Trehanpati N. Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN. Hepatology Communications. 2023 May 1;7(5):e0098.
22 Kumar K, Jagdish RK, Roy A, Premkumar M, Sharma M, Rao PN, Reddy DN, Kulkarni AV. Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure. Frontiers in medicine. 2023 Jun 15;10:1060073.
23 Kumar K, Kulkarni AV, Krishna V, Sharma M, Patodiya B, Khan A, Shaik S, Pasumarthy A, Chhabra P, Da PK, Saraswat VA. Safety and efficacy of atezolizumab-bevacizumab in real world: the first Indian experience. Journal of Clinical and Experimental Hepatology. 2023 Jul 1;13(4):618-23.
24 Kumar K, Kulkarni AV, Tevethia H, Premkumar M, Muttaiah MD, Hiraoka A, Hatanaka T, Tada T, Kumada T, Kakizaki S, Vogel A. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. EClinicalMedicine. 2023 Sep 1;63.
25 Kumar K, Kulkarni AV, Arab JP. Role of prophylactic antibiotics in patients with severe alcohol-related hepatitis. Journal of Clinical and Experimental Hepatology. 2023 Nov 1;13(6):1146-8.
26 Kumar K, Jindal A, Gupta E, Trehanpati N, Shasthry SM, Maiwall R, Arora V, Bhardwaj A, Kumar G, Kumar M, Sarin SK. Long term HBsAg responses to peg-interferon alpha-2b in HBeAg negative chronic hepatitis B patients developing clinical relapse after stopping long-term nucleos (t) ide analogue therapy. Journal of Clinical and Experimental Hepatology. 2024 Jan 1;14(1):101272.
27 Kumar K, Acharya SK, Singh SP, Duseja A, Madan K, Shukla A, Arora A, Anand AC, Bahl A, Soin AS, Sirohi B. 2023 update of Indian national association for study of the liver consensus on management of intermediate and advanced hepatocellular carcinoma: the Puri III recommendations. Journal of Clinical and Experimental Hepatology. 2024 Jan 1;14(1):101269.
28 Kumar K, Mehta NN, Shah H, Nagar A, Mahala VK, Nimje G, Jain AK, Saraswat VA. Transforming lives: A triumph of public-private partnership in successful liver transplants. Indian Journal of Gastroenterology. 2024 Apr;43(2):527-9.
29 Kumar K, Roy A, Premkumar M, Sree A, Gupta A, Sharma M, Alla M, Iyengar S, Venishetty S, Ghoshal UC, Goenka M. Current status of etiology and outcomes of acute liver failure in India—A multicentre study from tertiary centres. Indian Journal of Gastroenterology. 2025 Feb;44(1):47-56.
30 Kumar K, Kulkarni AV, Venishetty S, Gurav N, Albhaisi S, Chhabbra P, Shaik S, Alla M, Iyengar S, Sharma M, Rao PN. Impact of Karnofsky performance status on outcomes of patients with severe alcohol-associated hepatitis: a propensity-matched analysis. Internal Medicine Journal. 2025 Jan;55(1):109-16.
31 Kumar K, Choudhury A, Kulkarni AV, Arora V, Soin AS, Dokmeci AK, Chowdhury A, Koshy A, Duseja A, Kumar A, Mishra AK, Patwa AK. Acute-on-chronic liver failure (ACLF): the ‘Kyoto Consensus’—steps from Asia. Hepatology International. 2025 Feb;19(1):1-69.
32 Kumar K, Singh SP, Kulkarni A, Arora V, Choudhury A, Chaubal A, Rathi S, Shah S, Taneja S, Kumar A, Duseja A. Predictors of Non-response to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma: A Multicentre Real World Study (HCC-AB Study). Journal of Clinical and Experimental Hepatology. 2025 Jul 1;15(4):102513.
33 Kumar K, Mehta, N.N., Rajput, M., Nagar, A., Mahala, V.K., Saraswat, V.A. and Mishra, A., 2025. Evaluation of Controlled Attenuation Parameter as a Tool for Assessment of Hepatic Steatosis in Living Liver Donors. Journal of Clinical and Experimental Hepatology, 15(4), p.102514.
34 Kumar K, Saraswat VA. Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma in 2025. Journal of Clinical and Experimental Hepatology. 2025 Sep 1;15(5):102547.
35 Kumar K, Roy A, Kulkarni AV. Therapeutic Options for Alcohol-Associated Hepatitis in Resource-Limited Settings. Current Hepatology Reports. 2025 Oct 27;24(1):33.
36 Kumar K, Ghanta, H. and Saraswat, V.A., 2025. From guidelines to practice: Evaluating real-world adherence and knowledge-attitude–practice in HBV mother-to-child transmission prevention. Indian Journal of Gastroenterology, pp.1-2.
37 Kumar K, Kulkarni AV, , Giri S, Arab JP, Venishetty S, Premkumar M, Kadnur HB, Sharma M, Alla M, Iyengar S, Nayak G. Infections in standard or tapered dose of prednisolone for alcohol-associated hepatitis: a randomized trial (STASH trial). Official journal of the American College of Gastroenterology| ACG. 2022 May 12:10-4309.
38 Kumar K, Saraswat V, Kumar A, Kulkarni AV, Goel A, Shukla A, Duseja A, Dhiman RK, Aggarwal R. Nor-ursodeoxycholic acid for metabolic dysfunction-associated steatotic liver disease: is there enough evidence for clinical use? A critique of a phase III trial and regulatory endorsement of the drug. Journal of Clinical and Experimental Hepatology. 2026 Mar 9.
39 Kumar K, Shah HS, Mehta NN, Jain AK, Mahala VK, Saraswat VA. Clinical Profile and Prognostic Predictors in Hepatitis A Virus-Induced Acute Liver Failure. Journal of Clinical and Experimental Hepatology. 2026 Jan 23:103471.
book Book an Appointment
academic Specialities
phone Patient Support
bars Menu

Book an Appointment

arrow arrow
International Patient
Test & Health Packages
Careers
Contact Us